Ergogenic Properties of Magnesium Supplementation
- Conditions
- Exercise PerformanceGut -MicrobiotaMitochondrial Function
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: ReMag
- Registration Number
- NCT05282693
- Lead Sponsor
- Christopher Bell
- Brief Summary
The purpose of the proposed project is to determine if short-term dietary supplementation of magnesium will improve performance during a series of lab-based exercise tests, will favorably modify the gut-microbiota, and will augment skeletal muscle mitochondrial function.
- Detailed Description
Magnesium is the fourth most abundant mineral in the human body. It is critical to day-to-day physiological function including the regulation of metabolism, cardiovascular function, immune function, and the operation of the nervous system. In light of its important role in physiology, dietary supplementation of magnesium has been purported to improve athletic performance, although the precise mechanism is unclear. The foci of the proposed study is the ergogenic effects of magnesium, its potential influence on gut health, and its potential ability to improve skeletal muscle function. The investigators will be studying an athletic/competitive population of endurance-trained adults. This group is likely to be the most interested in the use of magnesium to enhance athletic performance. Also, by only recruiting habitual exercisers, the variability between participants is likely to be reduced compared with if the investigators had also recruited people who are usually sedentary.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 41
- Competitive cyclists
- Adult males and females (18 - 40 years, inclusive) who have exercised a minimum of 5 days per week, for a minimum of 30-minutes/session, during the previous 2 years.
- Maximal oxygen uptake (VO2max) satisfying the minimum criteria for "Good" (sex- and age-adjusted) as defined by the American College of Sports Medicine.
- Identification of a contra-indication to exercise during a 12-lead exercise stress test
- Use of a magnesium supplement within the previous 4 weeks
- Pregnancy or breast-feeding
- Unable to perform vigorous exercise
- History (previous diagnosis) of kidney disease
- Use of laxatives, Zinc, diuretics, proton pump inhibitors, over the counter agents such as certain heartburn and GI/gut treatments (laxatives) which contain magnesium, Zinc or other high dose cations which reduce absorption of Magnesium
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description ReMag Placebo Placebo Liquid Lemon flavor drink placebo comparator consumed twice daily for 9 days. ReMag ReMag Liquid Lemon flavor drink containing 300 mg magnesium chloride (Regmag) consumed twice daily for 9 days
- Primary Outcome Measures
Name Time Method Comparison interleukin 13 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison of indirect Calorimetry (VO2max) to placebo After 8 days of intervention During a standard stress test VO2 max will be measured
Comparison interleukin 2 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison of power output to placebo After 9 days of intervention Cycling for 30 seconds
Comparison of lactate threshold to placebo After 8 days of intervention During a standard stress test lactate threshold will be measured
Comparison interferon gamma to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison interleukin 1 beta to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison interleukin 7 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison interleukin 8 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison interleukin 10 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison High-sensitivity C-reactive protein to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison of completion of time trial to placebo After 9 days of intervention Amount of time it takes to cycle 10 kilometers
Comparison Human Granulocyte Macrophage Colony-Stimulating Factor to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison of Mitochondrial Function to placebo After 8 days of intervention Assessed via high-resolution mitochondrial respirometry in permeabilized skeletal muscle.
Determination of differentially abundant microbiota in feces of collected during treatment compared to placebo After 9 days of intervention Assessed via 16s ribosomal ribonucleic acid microbial profiling
Comparison Tumor Necrosis Factor alpha to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison of Shannon and Faith's microbiota diversity scores in feces to placebo After 9 days of intervention, Assessed via 16s ribosomal ribonucleic acid microbial profiling
Calculation and ordination of B-diversity scores for all fecal samples to assess clustering After 9 days of intervention Assessed via 16s ribosomal ribonucleic acid microbial profiling
Comparison of abundant microbiota to markers in feces to placebo After 9 days of intervention Assessed via Linear discriminant analysis Effect Size algorithm
Comparison interleukin 4 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison interleukin 5 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison interleukin 6 to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
Comparison interleukin 12 (p70) to placebo After 9 days of intervention Assessed via 13-plex human T-cell cytokine panel
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Colorado State University, Dept. of Health and Exercise Science
šŗšøFort Collins, Colorado, United States